These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11375740)

  • 41. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
    Shaffer CL; Scialis RJ; Rong H; Obach RS
    Biopharm Drug Dispos; 2012 Mar; 33(2):72-84. PubMed ID: 22213407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.
    Yao C; Levy RH
    J Pharm Sci; 2002 Sep; 91(9):1923-35. PubMed ID: 12210040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of a cocktail approach to screen cytochrome P450 BM3 libraries for metabolic activity and diversity.
    Reinen J; Postma G; Tump C; Bloemberg T; Engel J; Vermeulen NP; Commandeur JN; Honing M
    Anal Bioanal Chem; 2016 Feb; 408(5):1425-43. PubMed ID: 26753974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adaptation of high-throughput screening in drug discovery-toxicological screening tests.
    Szymański P; Markowicz M; Mikiciuk-Olasik E
    Int J Mol Sci; 2012; 13(1):427-52. PubMed ID: 22312262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Profiling drug-like properties in discovery research.
    Di L; Kerns EH
    Curr Opin Chem Biol; 2003 Jun; 7(3):402-8. PubMed ID: 12826129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.
    Vogt A; Lazo JS
    Pharmacol Ther; 2005 Aug; 107(2):212-21. PubMed ID: 15925410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of semi-automated metabolite identification software in the drug discovery process for rapid identification of metabolites and the cytochrome P450 enzymes responsible for their formation.
    Ramanathan R; McKenzie DL; Tugnait M; Siebenaler K
    J Pharm Biomed Anal; 2002 Jun; 28(5):945-51. PubMed ID: 12039637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of drug metabolism: the case of cytochrome P450 2D6.
    Vermeulen NP
    Curr Top Med Chem; 2003; 3(11):1227-39. PubMed ID: 12769702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Automated sample preparation and LC-MS for high-throughput ADME quantification.
    O'Connor D
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):52-8. PubMed ID: 11865673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
    Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic stability and its role in the discovery of new chemical entities.
    Słoczyńska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Żelaszczyk D; Popiół J; Pękala E
    Acta Pharm; 2019 Sep; 69(3):345-361. PubMed ID: 31259741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
    Gan J; Ma S; Zhang D
    Drug Metab Rev; 2016 Nov; 48(4):473-501. PubMed ID: 27533622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of drug metabolism in drug discovery and development.
    Kumar GN; Surapaneni S
    Med Res Rev; 2001 Sep; 21(5):397-411. PubMed ID: 11579440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The emerging importance of predictive ADME simulation in drug discovery.
    Selick HE; Beresford AP; Tarbit MH
    Drug Discov Today; 2002 Jan; 7(2):109-16. PubMed ID: 11790621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
    Pelkonen O; Turpeinen M; Uusitalo J; Rautio A; Raunio H
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):167-75. PubMed ID: 15733211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
    Isin EM; Elmore CS; Nilsson GN; Thompson RA; Weidolf L
    Chem Res Toxicol; 2012 Mar; 25(3):532-42. PubMed ID: 22372867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.